DGAP-News: Vita 34 quadruples earnings with a clear increase in margins
DGAP-News: Vita 34 AG / Key word(s): Quarter Results
Vita 34 quadruples earnings with a clear increase in margins
From a regional perspective, the development of the foreign subsidiaries is stable with a fundamentally positive overall trend. The change of the distribution partner in Serbia and Italy is developing positively. For 2019, therefore, the Executive Board expects that the change will result in a resumption of the growth trend in the regions concerned. In Denmark, after discontinuing its own sales activities, a partnership was entered into with a hospital chain based in Copenhagen, which already led to first deposits from the region in the third quarter. At the same time, the significantly lower cost base means that the region will have a positive effect on the consolidated result from the fourth quarter onwards with a significant improvement in earnings.
In the DACH region with its core market Germany, the number of storages continues to rise consistently. "Every month, we succeed in convincing expectant parents of the unique opportunities offered by the storage of their child's umbilical cord blood," Dr. Wolfgang Knirsch, CEO of Vita 34 AG, highlights. "Based on long-term contracts with our partner clinics, through which we have meanwhile secured a market coverage of 96 percent, we have the ideal basis for further profitable growth in Germany in the future. With the contract model Vita PUR, we will open up new sales channels."
Against the backdrop of continued positive business development and promising incoming orders, the Executive Board confirms its full-year guidance for 2018. The full report on the company's development in the first nine months as well as further information on Vita 34 AG can be found on the company's website at www.vita34.de/investor-relations/.
Vita 34 AG
Phone: +49 (0341) 48792 - 0
Mobile: +49 (0174) 9091190
Vita 34 was founded in Leipzig in 1997 as the first private cord blood bank in Europe and, as a complete provider of cryo-preservation services, offers collection, logistics, preparation, and storage of stem cells from umbilical cord blood and tissue. Stem cells are a valuable base material for medical cell therapy and are kept alive at temperatures of minus 200 degrees Celsius in order to be available for use in a treatment if needed. More than 200,000 customers from more than 20 countries have already provided for their family's health with a stem cell depot at Vita 34.
|Company:||Vita 34 AG|
|Deutscher Platz 5a|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|End of News||DGAP News Service|